From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

We need to diversify our HIV workforce with new roles that align with the health and well-being ... scientist with clinical ...

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus ...

Along with concepts like cure, remission, and control, it also helps to understand where vaccines fit in. As Jessica Salzwedel, the senior programme manager for research engagement at New York-based ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

The study from Tulane University found that those living in once-redlined neighborhoods see 15% longer delays in achieving successful viral suppression of HIV compared to those in non-redlined areas.

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

“These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and ...

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...